New drug combo aims to shrink breast tumors before surgery

NCT ID NCT07197697

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy before surgery can improve tumor response in 30 patients with HR+/HER2- breast cancer. The study uses a two-stage design to check if enough patients achieve a complete response (no cancer found after surgery). If successful, the drug combination may be studied further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iparomlimab and tuvonralimab (immunotherapy drugs) combined with chemotherapy (epirubicin, cyclophosphamide, paclitaxel)
What this could lead to
If successful, this could lead to a new treatment option that shrinks tumors before surgery in HR+/HER2- breast cancer, potentially improving outcomes.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The combination therapy may cause side effects like immune reactions or chemotherapy toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.